CG Oncology (CGON) Treasury Shares (2025 - 2026)
CG Oncology (CGON) reported Treasury Shares of $165373.0 for Q1 2026, down 0.58% quarter-over-quarter from $166342.0 in Q4 2025.
CG Oncology (CGON) Treasury Shares (2025 - 2026) Analysis & Trends
CG Oncology has reported Treasury Shares for 2 years, with the latest figure at $165373.0 in Q1 2026.
- For the quarter ending Q1 2026, Treasury Shares changed N/A year-over-year to $165373.0; the trailing twelve-month figure through Mar 2026 stood at $165373.0 (changed N/A YoY), and the FY2025 full-year result was $166342.0, changed N/A from the prior year.
- Treasury Shares for Q1 2026 stood at $165373.0, down from $166342.0 in the prior quarter.
- The five-year high for Treasury Shares was $166342.0 in Q4 2025, with the low at $94624.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 700,000.00 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | CG Oncology | 5.04 Bn | 5.04 Bn | -1.88 Mn | 165,373.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 165,373.00 |
| Mar 31, 2026 | 165,373.00 |
| Dec 31, 2025 | 166,342.00 |
| Dec 31, 2025 | 166,342.00 |
| Sep 30, 2025 | 94,624.00 |
| Sep 30, 2025 | 94,624.00 |